What you are asking for is the statistical analysis plan. I agree it is something that companies should be forced to release by the ASX, but it is not required and few companies do. DXB could also have released the blinded composite results and side effects if they wished, but they have chosen not to.
There is a case to be made that biotechs should have to meet some JORC like standard on disclosure, but until the ASX choose to act on this, as investors we will often get less data than is ideal for making an informed decision.
What you are asking for is the statistical analysis plan. I...
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $175.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 31.5¢ | $1.783M | 5.386M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 92430 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 94413 | 2 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
32.5¢ |
Change
-0.015 ( 2.99 %) |
||||
| Open | High | Low | Volume | ||
| 34.0¢ | 34.5¢ | 32.0¢ | 2631979 | ||
| Last updated 15.59pm 01/05/2024 ? | |||||
| DXB (ASX) Chart |